Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2236 to 2250 of 9088 results

  1. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  2. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Semaglutide 7.2 mg dose for managing obesity ID6699

    In development Reference number: GID-TA11920 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Vamikibart for treating uveitic macular oedema ID6671

    In development Reference number: GID-TA11885 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Helge for detecting haemolysis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  8. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

    Topic prioritisation

    Topic prioritisation

  9. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  10. Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

    In development Reference number: GID-TA11334 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke

    In development Reference number: GID-HTG10881 Expected publication date:  11 February 2027

    HealthTech guidance
    In development